MUSILOVÁ, Milena, Filip RÁZGA, Tomáš JURČEK, Ivana JEŽÍŠKOVÁ, Marek BORSKÝ, Veronika NÉMETHOVÁ, Daniela ŽÁČKOVÁ, Martin ČULEN, Dana DVOŘÁKOVÁ, Jiří MAYER a Zdeněk RÁČIL. BCR-ABL1 kinase domain mutational analysis of CD34+ stem/progenitor cells in newly diagnosed CML patients by next-generation sequencing. American Journal of Hematology. Wiley-Blackwell, 2014, roč. 89, č. 10, s. 1016-1017. ISSN 0361-8609. Dostupné z: https://dx.doi.org/10.1002/ajh.23794. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1216596, author = {Musilová, Milena and Rázga, Filip and Jurček, Tomáš and Ježíšková, Ivana and Borský, Marek and Némethová, Veronika and Žáčková, Daniela and Čulen, Martin and Dvořáková, Dana and Mayer, Jiří and Ráčil, Zdeněk}, article_number = {10}, doi = {http://dx.doi.org/10.1002/ajh.23794}, keywords = {BCR-ABL; CD34+; CML; next generation sequencing}, language = {eng}, issn = {0361-8609}, journal = {American Journal of Hematology}, title = {BCR-ABL1 kinase domain mutational analysis of CD34+ stem/progenitor cells in newly diagnosed CML patients by next-generation sequencing}, volume = {89}, year = {2014} }
TY - JOUR ID - 1216596 AU - Musilová, Milena - Rázga, Filip - Jurček, Tomáš - Ježíšková, Ivana - Borský, Marek - Némethová, Veronika - Žáčková, Daniela - Čulen, Martin - Dvořáková, Dana - Mayer, Jiří - Ráčil, Zdeněk PY - 2014 TI - BCR-ABL1 kinase domain mutational analysis of CD34+ stem/progenitor cells in newly diagnosed CML patients by next-generation sequencing JF - American Journal of Hematology VL - 89 IS - 10 SP - 1016-1017 EP - 1016-1017 PB - Wiley-Blackwell SN - 03618609 KW - BCR-ABL KW - CD34+ KW - CML KW - next generation sequencing N2 - Mutations in the BCR-ABL1 kinase domain (KD) represent one of the most important causes of resistance to tyrosine kinase inhibitors (TKIs) treatment in patients with chronic myeloid leukemia (CML). The resistance-causing mutations are hypothesized to expand directly from the stem and/or progenitor cells and are present in CD341 cells significantly earlier than they occur in bone marrow or peripheral blood. Thus, early detection of these mutations is of great importance, since it can affect the subsequent TKI therapy. ER -
MUSILOVÁ, Milena, Filip RÁZGA, Tomáš JURČEK, Ivana JEŽÍŠKOVÁ, Marek BORSKÝ, Veronika NÉMETHOVÁ, Daniela ŽÁČKOVÁ, Martin ČULEN, Dana DVOŘÁKOVÁ, Jiří MAYER a Zdeněk RÁČIL. BCR-ABL1 kinase domain mutational analysis of CD34+ stem/progenitor cells in newly diagnosed CML patients by next-generation sequencing. \textit{American Journal of Hematology}. Wiley-Blackwell, 2014, roč.~89, č.~10, s.~1016-1017. ISSN~0361-8609. Dostupné z: https://dx.doi.org/10.1002/ajh.23794.
|